

20 March 2024 EMA/HMPC/493453/2023 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on *Pilosella* officinarum Vall. (syn *Hieracium pilosella* L.), herba cum radice

Draft - Revision 1

Initial assessment	
Discussion in Working Party on European Union monographs and	November 2013
European Union list (MLWP)	January 2014
	March 2014
	May 2014
Adopted by Committee on Herbal Medicinal Products (HMPC) for	1 July 2014
release for consultation	1 301,7 201 1
End of consultation (deadline for comments)	31 October 2014
Rediscussion in MLWP	November 2014
	January 2015
Adoption by HMPC	
Monograph (EMA/HMPC/680374/2013)	
Assessment Report (EMA/HMPC/680373/2013)	5 May 2015
List of References (EMA/HMPC/35510/2014)	
HMPC Opinion (EMA/HMPC/165127/2015)	
First systematic review	
Discussion in HMPC	March 2023
	May 2023
	July 2023
Adopted by HMPC for release for consultation	20 March 2024
Start of public consultation	15 April 2024
End of consultation (deadline for comments). Comments should be	15 July 2024
provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u> .	== == , === :



#### Keywords

Committee on Herbal Medicinal Products; HMPC; European Union herbal monographs; herbal medicinal products; traditional use; *Pilosella officinarum* Vall. (syn *Hieracium pilosella* L.), herba cum radice; Pilosellae herba cum radice; Mouse-ear hawkweed

BG (bălgarski): Рунянка, стрък с корен

CS (čeština): nať jestřábníku chlupáčku s

kořenem

DA (dansk): Håret gøgeurt

DE (Deutsch): Kleines Habichtskraut mit Wurzeln

EL (elliniká): πιλοσέλλας πόα με ρίζα

EN (English): Mouse-ear hawkweed

ES (español): vellosilla, partes aéreas con raíz de

ET (eesti keel): karutubakaürt koos juurtega

FI (suomi): huopakeltano, verso juurineen

FR (français): piloselle (plante entière de)

HR (hrvatski): zelen s korijenom male runjike

HU (magyar): ezüstös hölgymál virágos hajtás

gyökérrel

IT (italiano): Pilosella parti aeree fiorite con radice

LT (lietuvių kalba): Kudlių žolė su šaknimis

LV (latviešu valoda): Mazās mauragas laksts ar sakni

MT (Malti): ħaxixa bl-għeruq tal-heraċju

NL (Nederlands): Muizenoor, kruid en wortel

PL (polski): ziele jastrzębca kosmaczka z

korzeniem

PT (português): pilosela, partes aéreas e raízes

RO (română): iarba si radcina de vulturica

SK (slovenčina): vňať chlpánika s koreňom

SL (slovenščina): zel in korenina dolgodlakave

škržolice

SV (svenska): gråfibbla, ört och rot

IS (íslenska):

NO (norsk): hårsveve, urt med rot

# European Union herbal monograph on *Pilosella officinarum* Vall. (syn *Hieracium pilosella* L.), *herba cum radice*

# 1. Name of the medicinal product

To be specified for the individual finished product.

# 2. Qualitative and quantitative composition<sup>1, 2</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice (Mouse-ear hawkweed)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparations
	a) Comminuted herbal substance
	b) Powdered herbal substance

#### 3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparations in solid or liquid dosage forms for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

### 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used for the relief of symptoms associated with minor urinary tract complaints in addition to the

<sup>&</sup>lt;sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>&</sup>lt;sup>2</sup> The material complies with the Ph. Fr. monograph (Piloselle)

Well-established use	Traditional use
	general recommendation of a sufficient fluid intake to increase the amount of urine.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

# 4.2. Posology and method of administration

Well-established use	Traditional use
Posology	Posology
Duration of use	Adults and elderly
	a) Herbal tea
Method of administration	Single dose: 2-4 g of the comminuted herbal substance in 250 ml of boiling water as an herbal infusion, 3 times daily.
	b) Powdered herbal substance:
	Single dose: 200-520 mg, 2-4 times daily. Daily dose: 560 mg up to 1300 mg.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

#### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance(s) and to other plants of the Asteraceae (Compositae) family.

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.
	If complaints or symptoms such as fever, dysuria, spasms, or blood in urine occur during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Because adequate fluid intake is required during treatment, <i>Pilosella officinarum</i> Vall. (syn <i>Hieracium pilosella</i> L.), herba cum radice is not recommended for patients with conditions where reduced fluid intake is advised.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

#### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.  No fertility data available.

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	None known.

Well-established use	Traditional use
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

# 5. Pharmacological properties

# 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

# 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

# 7. Date of compilation/last revision

20 March 2024